The role of adhesion and costimulation molecules in graft-versus-host disease

Acta Haematologica

Volumn 97, Issue 1-2, 1997, Pages 105-117

  Schlegel, Paul G ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adhesion; Costimulation; Graft versus host disease; Homing

Indexed keywords

CELL ADHESION MOLECULE; IMMUNOGLOBULIN; INTEGRIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; SELECTIN; T LYMPHOCYTE RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTATION; CLONAL ANERGY; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; BONE MARROW TRANSPLANTATION; CELL ADHESION MOLECULES; CELL MOVEMENT; GRAFT VS HOST DISEASE; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; RECEPTORS, INTERLEUKIN-2; RECEPTORS, LYMPHOCYTE HOMING; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 15444346566     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203666     Document Type: Article

References (164)

1. Forman SJ, Blume KG, Thomas DE: Bone Marrow Transplantation. Oxford, Oxford University Press, 1994.
2. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC. Long GD, Nademance AP. Negrin RS, O'Donnell MR, Parker PM. Smith EP. Snyder DS, Stein AS, Wong RM. Blume KG. Forman SF: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993:329: 1225-1230.
3. Chao NJ, Schlegel PG: Prevention and treatment of graft-versus-host disease. Ann NY Acad Sei 1995;770:130-140.
4. Billingham R: The biology of graft-versus-host reaction. 1966. Harvey Lecture 21.
5. Chao NJ: Graft-vcrsus-Host Disease. Austin. Landes, 1994.
6. Miconnet I, Huchet R. Bonardelle D, Motta R, Canon C. Garay-Rojas E, Kress M. Reynes M. Halle-Panncnko O, Bruley-Rosset M: Graft-versus-host mortality induced by noncytolytic CD4* T cell clones specific for non-H-2 antigens. J Immunol 1990;145:2123-2131.
7. Sakamoto H. Michaelson J. Jones WK, Bhan AK, Abhyankar S, Silverstein M. Golan DE, Burakoff S, Ferrara JLM: Lymphocytes with a CD4*CD8‘CD3’ phenotype arc effectors of experimental graft-versus-host disease. Proc Natl Acad Sei USA 1991;88:10890-10894. Hamilton BL: L3T4-positivcT cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987;39:2511-2515.
8. Komgold R, Sprcnt J: Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987; 165:1552- 1564.
9. Truitt RL. Atasoylu AA: Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991;8:51-58.
10. Komgold R: Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: Features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant 1992: 9:355-364.
11. Komgold R. Sprent J: T-cell subsets in graft-vs.-host disease: in Burakoff SJ. Deeg HJ, Ferrara J. Atkinson K (eds): Graft-vs.-Host Disease. Immunology. Pathophysiology, and Treatment. New York, Marcel Dekker, 1990, pp 31-49.
12. Parkman R: Clonal analysis of murine graft-versus-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986;136:3543-3548.’
13. Perreault C, Décary F, Brochu S, Gyger M, Belanger R, Roy D: Minor histocompatibility antigens. Blood 1990;76:1269-1280.
14. Lindahl KF: Minor histocompatibility antigens. Trends Genet 1991;7:219-224.
15. Griem P. Wallny HJ. Falk K. Rötzschke O. Arnold B, Schönrich G, Hämmerling G, Ram-menscc HG: Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 1991;65: 633-640.
16. den Haan JM, Sherman NE, Blokland E, Hucz-ko E. Koning F. Drijfhout JW, Skipper J, Sha-banowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
17. Wang W, Meadows LR, den Haan JMM, Sherman NE, Chen Y, Blokland E. Shabanowitz J, Agulnik Al, Hendrickson RC, Bishop CE, Hunt DF. Goulmy E, Engelhard VH: Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
18. Speiser DE. Zürcher T, Ramseicr H, Hengart-ner H, Stacheli P, Haller O, Zinkcmagel RM: Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen. Proc Natl Acad Sei USA 1990;87:2021-2025.
19. Wallny PJ. Rammensee HG: Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990:343:275- 278.
20. Knulst AC, Bril-Bazuin C, Benner R: Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T-cell monoclonal antibody to the allograft recipients. Eur J Immunol 1991:21:103-107.
21. Claman HN. Jaffce BD, HufT JC, Clark RA: Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depiction with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985;94:73-84.
22. Ferrara J. Guillen FJ, van Dijken PJ, Marion A. Murphy GF. Burakoff. SJ: Evidence that large granular lymphocyte of donor origin mediate acute graft-versus-host disease. Transplantation 1989:47:50-54.
23. Cipriano D. Faanes R. Merluzzi VJ: Protection of mice against acute lethal graft-versus-host disease by treatment with anti-asialo GM1 antibody: Alopecia dermatitis in long-term survivors. Transplantation 1989;47:922-924.
24. Chao NJ: Graft-versus-host disease. Curr Opin Immunol 1992;4:571-576.
25. Harlan JM, Liu DY: Adhesion: Its Role in Inflammatory Disease. New York. Freeman. 1992.
26. Carlos TM. Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 1994:84:2068- 2101.
27. Siegelman MH, Weissman 1L: Human homo-logue of mouse lymph node homing receptor: Evolutionary conservation al tandem cell interaction domains. Proc Nall Acad Sci USA 1989; 86:5562-5566.
28. Siegelman MH. van de Rijn, Weisman IL: Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science 1989:243:1165-1172.
29. D. Fennie Cloning of a lymphocyte homing receptor reveals a lectin domain. Cell 1989:56: 1045-1055.
30. Walcheck B. White M. Kurk S. Kishimoto TK. Jutila MA: Characterization of the bovine peripheral lymph node homing receptor: A lectin cell adhesion molecule (LECAM). Eur J Immunol 1992;22:469-476.
31. Kishimoto TK, Jutila MA. Butcher EC: Identification of a human peripheral lymph node homing receptor: A rapidly down-regulated adhesion molecule. Proc Natl Acad Sci USA 1990;87:2244-2248.
32. Jung TM, Dailey MO: Rapid modulation of homing receptors induced by activators of protein kinase C: Receptor shedding due to accelerated proteolytoc cleavage at the cell surface. J Immunol 1990; 144:3130-3136.
33. Schleiffcnbaum B. Spcrtini O. Tedder TF: Soluble L-selcctin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992:119:229-238.
34. 3. Biochcm Biophys Res Commun 1992:184:1048-1055.
35. Foxall C, Watson SR. Dowbenko D, Fennie C, Lasky LA. Kiso M. Hasegawa A. Asa D. Brand-ley BK: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis' oligosaccharide. J Cell Biol 1992;117:895-902.
36. Lasky LA, Singer MS. Dowbenko D. Imai Y. Henzcl WJ, Grimlcy C, Fennie C, Gillet N, Watson SR, Rosen SD: An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 1992;69:927-938.
37. Dowbenko D, Andalibi A. Young PE. Lusis AJ. Lasky LA: Structure and chromosomal localization of the murine gene encoding glvcam-l: A mucin-like endothelial ligand for L-selectin. J Biol Chem 1993:268:4525-4529.
38. Shimizu Y. Shaw S: Mucins in the mainstream. Nature 1993;366:630-631.
39. Bevilacqua MP. Pober JS. Mendrick DL. Co-tran RS, Gimbronc MA Jr.: Identification of an inducible cndothclial-lcukocytc adhesion molecule. Proc Natl Acad Sci USA 1987:84:9238-9242.
40. Hsu-Lin SC. Berman CL, Furie BC, August D. Furic B: A platelet membrane protein expressed during platelet activation and secretion. J Biol Chem 1984:259:9121-9126.
41. Bonfanti R, Furie BC, Furie B. Wagner DD: PADGEM (GMP-!40) is a component of Wei-bcl-Palade bodies of human endothelial cells. Blood 1989;73:1109-1112.
42. McEver RP, Beckstcad JH. Moore KL. Mar-shall-Carlson L, Bui won DF: GMP-140, a platelet ot-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibcl-Paladc bodies. J Clin Invest 1989:84:92-99.
43. Johnston GI. Cook RG. McEver RP: Cloning of GMP-140. a granule membrane protein of platelets and endothelium: Sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989:56:1033-1044.
44. Erbe DV, Watson SR. Presta LG. Wolitzky BA. Foxall C. Brandley BK, Lasky LA: P- and E-selectin use common sites for carbohydrate ligand recognition and cell adhesion. J Cell Biol 1993;120:1227-1227.
45. Hollcnbaugh D. Bajorath J. Stcnkamp R. Aruf-fo A: Interaction of P-selectin and its cellular ligand: Analysis of critical residues. Biochemistry 1993:32:2960-2966.
46. Dunlop LC. Skinner MP. Bendall U. Favaloro EJ, Castaldi PA. Gorman JJ, Gamble JR. Vad-as MA, Berndl MC: Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175:1147-1150.
47. Stoolman LM, Nair RP. Larsen RD. Bcrhend TL, Marks RM: ELAM-l-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransfcr-ase. Cell 1990:63:475-484.
48. x determinant on myeloid and tumor cells. Science 1990:250:1132-1135.
49. Goelz SE, Hession C. Goff D. Griffiths B. Tizard R. Newman B. Chi-Rosso G. Lobb R: ELFT: A gene that directs the expression of an ELAM-1 ligand. Cell 1990:63:1349-1356.
50. x, an E-selcctin ligand, in inflammation, immune processes, and lymphoid tissues. Am J Pathol 1992:141:1397-1408.
51. Ohmori K, Yoneda T. Ishihara G. Shigcta K. Hiroshima K, Kanai M, Itai S. Sasaoki T, Aril S, Arita H. Kannagi R: Sialyl SSEA-I antigen as a carbohydrate marker on human natural killer cells and immature lymphoid cells. Blood 1989;74:255-261.
52. Ohmori K, Yoneda T. Ishihara G. Shigcta K. Hiroshima K, Kanai M, Itai S.: Differentiation-dependent expression of sialyl stage-specific embryonic antigcn-I and I-antigens on human lymphoid cells and its implications for carbohydrate-mediated adhesion to vascular endothelium. Blood 1993:81: 101-111.
53. Berg EL, Yoshino T, Rotl LS. Robinson MK. Warnock RA, Kishimoto TK. Picker LJ. Butcher EC: The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for vascular lectin endothelial cell-lcukocytc adhesion molecule-1. J Exp Med 1991:174:1461-1466.
54. x is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem 1991:266: 14869-14872.
55. Handa K. Neudclman: Sclectin GMP-140 (CD62: PADGEM) binds to sialosyl-Lex and sialosyl-Lea. and sulfated glycans modulate this binding. Biochem Biophys Res Commun 1991; 181: 1223-1230.
56. Sako D. Chang X-J, Barone KM. Vachino G, White HM. Shaw G. Vcldman GM. Bean KM. Ahern TJ. Furic B, Cumming DA, Larsen GR: Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 1993:75:1179-1186.
57. Lentcr M, Levinovitz A, Monospecific and common glycoprotein ligands for E- and P-selectin on myeloid cells. J Cell Biol 1994:125:471-481.
58. Staunton DE. Marlin SD. Stratowa C. Dustin ML. Springer TA: Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supcrgcne superfamilies. Cell 1988:52:925-933.
59. Simmons D. Makgoba MW. Seed B: ICAM, an adhesion ligand of LFA-1. is homologous to the neural cell adhesion molecule NCAM. Nature 1988;331:624-627.
60. Staunton DE, Dustin ML. Erickson HP. Springer TA: The arrangement of the immuno-globulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 1990: 61:243-254.
61. Diamond MS, Staunton DE, Marlin SD. Springer TA: Binding of the integrin Mac-1 (CD!lb/CD18) to the third immunoglobulinlike domain of ICAM-I (CD45) and its regulation by glycosylation. Cell 1991:65:961-971.
62. Mimura N. Asano A: Further characterization of a conserved actin-binding 27-kDa fragment of actinogclin and alpha-actinins and mapping of their binding sites on the actin molecule by chemical crosslinking. J Cell Biol 1987:262: 4717-4723.
63. Siu G. Hedrick SM. Brian AA: Isolation of the murine intercellular adhesion molecule-1 (ICAM-l)gcnc: ICAM-1 enhances antigen-specific T cell activation. J Immunol 1989:143: 3813-3820.
64. Kita Y. Takashi T. Iigo Y. Tamatani T. Miya-saki M. Horiuchi T: Sequence and expression of rat ICAM-I. Biochim Biophys Acta 1992: 1131:108-110.
65. Staunton DE, Dustin ML, Springer TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989:339:61-64.
66. Polte T. Newman W. Gopal TV: Full-length vascular cell adhesion molecule 1 (VCAM-I). Nucl Acids Res 1990:18:5901.
67. Hession C, Tizard R, Vassallo C. Schiffer SB. Goff D. Moy P. Chi-Rosso G, Luhowskj S. Lobb R, Osborn L: Cloning of an alternate form of vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1991:266:6682-6685.
68. Cybulsky ML Fries JWU, Williams AJ. Sultan P. Alternative splicing of human VCAM-I in activated vascular cell endothelium. Am J Pathol 1991;138:815-820.
69. Osborn L, Vasallo C. Benjamin CD: Activated endothelium binds lymphocytes through a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule-1. J Exp Med 1992;176:99-107.
70. Vonderheidc RH, Springer TA: Lymphocyte adhesion through very late antigen 4: Evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule I and an additional h4 integrin counter-receptor on stimulated endothelium. J Exp Med 1992:175:1433-1442.
71. Vonderhcide RH. Tedder TF. Springer TA. Staunton DE: Residues within a conserved amino acid motif of domains I and 4 of VCAM-I are required for binding to VLA-4. J Cell Biol 1994;125:215-222.
72. Andrew DP, Berlin C, Honda S. Yoshino T. Hamann A. Holzmann B. Kilshaw PJ. Butcher EC: Distinct but overlapping epitopes are involved in otP7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-l. fibronectin. and lymphocyte aggregation. J Immunol 1994:153:3847-3861.
73. Hession C. Moy P. Tizard R. Chisholm P. Williams C. Wysk M. Burkly L. Miyake K. Kin-cade P. Lobb R: Cloning of murine and rat vascular cell adhesion molecule-1. Biochem Bio-phys Res Commun 1992;183:163-169.
74. Williams C. Wysk M. Burkly L. Miyake K.: Nucleotide sequence of rat vascular cell adhesion molecule-1 cDNA. Biochim et Biophys Acta 1992: 1131:214-216.
75. Streeter PR. Berg EL. Rouse BI N, Bargatze RF. Butcher EC: A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988:331:41-46.
76. Nakachc M. Berg The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature 1989:337:179- 181.
77. Briskin MJ. McEnvoy LM. Butcher EC: MAd-CAM-I has homology to immunoglobulin and mucin-like adhesion receptors and to IgAl. Nature 1993:363:461-464.
78. Berlin C. Berg EL. Briskin MJ, Andrew DP. Kilshwa PJ. Holzmann B. Weissman IL. Hamann A. Butcher EC: ajp? integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993:74:185-195.
79. Zchndcr JL. Shatsky M. Leung LL, Butcher EC. McGregor JL. Levitt LJ: Involvement of CD31 in lymphocyte-mediated immune responses: Importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide. Blood 1995:85:1282-1288.
80. Chen Y. Schlegel PG, Tran N, Thompson D, Zchndcr JL, Chao NJ: Administration of a CD3l-derived peptide reduces lethal graft-versus-host disease across the minor histocompatibility complex barrier in mice. Blood 1995:86(suppl l):575.
81. Muller WA, Weigl SA, Deng X. Phillips DM: PECAM-I is required for transendothelial migration oflcukocytcs. J Exp Med 1993; 178: 449-460.
82. Vaporciyan AA, DeLisscr HM. Yan H-C, Mendiguren IL. Thom SR. Jones ML. Ward PA. Albelda SM: Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science 1993; 262:1580-1582.
83. Simmons DL. Walker C. Power C. Pigott R: Molecular cloning of CD31. a putative intercellular adhesion molecule closely related to carcinoembryonic antigen. J Exp Med 1990; 171:2147-2152.
84. Albelda SM. Muller WA. Buck CA. Newman PJ: Molecular and cellular properties of PE-CAM-1 (EndoCAM/CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol 1991: 114:1059-1068.
85. Tanaka Y. Albelda SM, Horgan KJ. van Sev-cnter GA. Shimizu Y, Newman W, Hallam J, Newman PJ. Buck CA. Shaw S: CD31 expressed on distinctive T cell subsets is a preferential amplifier of ßl integrin-mediatcd adhesion. J Exp Med 1992:176:245-253.
86. Tanaka Y. Albelda SM, Horgan KJ. van Sev-cnter GA: CD31/ PECAM-1 is a ligand for alpha vs. beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 1995; 130:451-460.
87. Springer TA: Adhesion receptors of the immune system. Nature 1990:346:425-434.
88. Hvncs RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25.
89. Smylh SS. Joneckis CC. Parise LV: Regulation of vascular integrins. Blood 1993:81: 2827-2843.
90. de Fougerolles AR. Springer TA: Intercellular adhesion molecule 3. a third countcr-reccptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 1992: 175:185-190.
91. Arnaout MA: Structure and function of the leukocyte adhesion molecule CD 11/CD 18. Blood 1990:75:1037-1050.
92. Forsyth KD. Levinsky RJ: Role of the LFA-1 adhesion glycoprotein in neutrophil adhesion to endothelium and plastic surfaces. Clin Exp Immunol 1989:75:265-268.
93. Arnaout MA. Lanier LL. Faller DV: Relative contribution of the leukocyte molecules Mol. LFA-I. and pl50/95(LeuM5) in adhesion of granulocytes and monocytes to vascular endothelium is tissue- and stimulus-specific. J Cell Physiol 1988:137:305-309.
94. Lo SK. van Seventer GA. Levin SM. Wright SD: Two leukocyte receptors (C'DI la/CDI8 and CDllb/CD!8) mediate transient adhesion to endothelium by binding to different ligands. J Immunol 1989;143:3325-3329.
95. Mcntzer SJ. Crimmins MAV. Burakoff SJ. Faller DV: Alpha and beta subunits of the LFA-1 membrane molecule arc involved in human monocyte-endothelial cell adhesion. J Cell Physiol 1987;130:410-415.
96. Harlan JM, Kinnlen PD, Senecal FM. Schwartz BR, Yee EK. Taylor RF. Beatty PG. Rice TH. Ochs HD: The role of neutrophil membrane glycoprotein GP150 in neutrophil adherence to endothelium in vitro. Blood 1985:66:167-178.
97. Dustin ML. Springer TA: Lymphocyte function-associated antigen (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988; 107:321-331.
98. Hemler ME: VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol 1990;8: 365-400.
99. Elices MJ, Osbom L. Takada Y. Crouse C, Luhowsky S. Hemler M. Lobb RR: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60:577-584.
100. Wayncr EA. Garcia-Pardo A, Humphries MJ. McDonald JA, Carter WG: Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibroncctin. J Cell Biol 1989:109:1321-1330.
101. Guan J-L, Hynes RO: Lymphoid cells recognize an alternatively spliced gment of fi-bronectin via the integrin receptor ojPi. Cell 1990:60:53-61.
102. Yabkowitz R. Dixit VM, Guo N. Roberts DD, Shimizu Y: Activated T-cell adhesion to thrombospondin is mediated by the juPi (VLA-4) and u
103. Bednarczyk JL. McIntyre BW: A monoclonal antibody to VLA-4 a chain (CD49wd) induces homotypic lymphocyte aggregation. J Immunol 1990:144:777-784.
104. Campanero MR, Pulido R. Ursa MA, Rodri-guez-Moya M. de Landazuri MO, Sanchez-Madrid F: An alternative leukocyte homotypic adhesion mechanism. LFA-l/ICAM-1 independent, triggered through the human VLA-4 integrin. J Cell Biol 1990:110:2157-2165.
105. Bednarczyk JL, Wygant JN, Szabo MC. Moli-nari-Storey L, Renz M, Fing S. McIntyre BW: Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for a novel epitope expressed by the integrin pi subunit: Conversion of nonresponsivc cells by transfecting human integrin a4 subunit cDNA. J Cell Biochcm 1993;51:465-478.
106. Erie DJ, Ruegg C, Sheppard D. Pytela R: Complete amino acid sequence of an intcgrin P subunit (pr) identified in leukocytes. J Biol Chcm 1991:266:11009-11016.
107. Jiang WM, Jenkins D. Yuan Q. Leung E, Choo KHA, Watson JD. Krissansen GW:Thc gene organization of the human p7 subunit, the common p subunit of the leukocyte integrin HML-I. Int Immunol 1992;4:1031- 1040.
108. Ruegg C. Postigo AA. Sikorski EE, Butcher EC. Ptyela R. Erie DJ: Role of intcgrin ajPp in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol 1992:117:179-189.
109. Postigo AA. Sanchez-Mateo P. Lazarovits AI. Sanchez-Madrid F, dc Landazuri MO: u_4 p? mediated B cell adhesion to fibroncctin and vascular cell adhesion molecule. 1. Expression and function of a4 integrins on human B lymphocytes. J Immunol 1993:151:2471-2483.
110. Mackay CR, Imhof BA: Cell adhesion in the immune system. Immunol Today 1993; 14: 99-102.
111. Vaddi K, Newton RC: Regulation of monocyte intcgrin expression by beta-family che-mokines. J Immunol 1994:153:4721-4732.
112. Dustin ML. Springer TA: L:T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-t. Nature 1989:341:619-624.
113. Cabanas C, Hogg N: Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule I. Proc Natl Acad Sci USA 1993:90:5838-5842.
114. Norton J, Sloane JP. Al-Saffar N, Haskard DO: Expression of vessel associated adhesion molecules in normal skin and acute graft-ver-sus-host disease. J Clin Pathol 1991:44:586-591.
115. Norton J. Sloane JP, Delia D, Greaves MF: Reciprocal expression of CD34 and cell adhesion molecule ELAM-1 on vascular endothelium in acute cutaneous graft-versus-host disease. J Pathol 1993;170:173-177.
116. Norton J. Sloane JP: ICAM-1 expression on epidermal kératinocytes in cutaneous graft-versus-host disease. T ransplantation 1991:51: 1203-1206.
117. Norton J. Sloane JP. al-Saffar N, Haskard DO: Expression of adhesion molecules in human intestinal graft-versus-host disease. Clin Exp Immunol 1992:87:231-236.
118. Roy J, Platt JL, Weisdorf DJ: The immuno-pathology of upper gastrointestinal acute graft-versus-host disease: Lymphoid cells and endothelial adhesion molecules. Transplantation 1993:55:572-578.
119. Norton J, al-Saffar N. Sloane JP: Adhesion molecule expression in human hepatic graft-versus-host disease. Bone Marrow Transplant 1992;10:153-156.
120. Tanaka T, Ohtsuka Y, Yagita H. Shiratori Y. Omata M. Okumura K: Involvement of the al and a4 intcgrins in gut injury of graft-versus-host disease. Int Immunol 1995:7:1183- 1189.
121. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990:248: 1349-1356.
122. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4. and B7/ BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068. Rothbard JB, Gefter ML: Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991:9:527-565.
123. Jenkins MK, Schwartz RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsivc-ness in vitro and in vivo. J Exp Med 1987; 165:302-319.
124. Kawakami K. Yamamoto Y, Kakimoto K. Onoue K: Requirement for delivery of signals by physical interactions and soluble factors from accessory cells in the induction of receptor-mediated T cell proliferation: Effectiveness of IFN gamma modulation of accessory cells for physical interaction with T cells. J Immunol 1989:142:1818-1825.
125. Ho WY. Cooke MP. Goodnow CC, Davis MM: Resting and anergic B cells arc defective in CD 28-dcpcndent costimulation of naive CD4+ T cells. J Exp Med 1994; 179:1539-1549.
126. 4 T cell: Receptor-dependent cytolysis in the absccncc of interleukin-2 production. Science 1991;251:1228-1231.
127. Tan P. Anasetti C. Hansen JA. Melrose J, Brunvand M. Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloanligen-spccific hyporesponsiveness in human T lymphocytes by blocking interaction of CD 28 with its natural ligand B7/BB1. J Exp Med 1993:177: 165-173.
128. Gitr.mi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-6590.
129. Hardning FA, McArthur JG, Gross JA, Rau-let DH, Allison JP: CD28-mediatcd signalling co-slimulatcs murine T cells and prevents induction of anergy in T-cell clones. Nature 1992:356:607-609.
130. Mueller DL. Jenkins MK. Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell receptor antigen occupancy. Annu Rev Immunol 1989;7:445-480.
131. Anasetti C. Tan P. Hansen JA. Martin PJ: Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigcn. J Exp Med 1990:172: 1691-1700.
132. van Seventer GA. Newman W, Shimizu Y. Nutman TB. Tanaka Y. Horgan KJ. Gopal TV, Ennis E, O’Sullivan D, Grey H. Shaw S: Analysis of T cell stimulation by superantigcn plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: Costimulation by purified adhesion ligands VCAM-1, ICAM-1. but not ELAM-1. J Exp Med 1991;174:901-913.
133. 4 T lymphocytes. J Immunol 1992:148: 1985-1992.
134. 3+ levels. J Immunol 1992:149: 3872-3880.
135. Damle NK, Klussman K, Leytzc G, Ochs HD. Aruffo A. Linsley PS. Ledbetter JA: Co-stinulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell Immunol 1993;148:144-156.
136. Murphy EE. Terres G, Macatonia SE. Hsieh CS. Mattson J. Lanier L, Wysocka M. Trin-cieri G. Murphy K, O’Garra A: B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-231.
137. Freeman GJ. Borriello F, Hodes RJ. Reiser H, Hathcock KS. Lazio G. McKnight AJ. Kim J, Du L. Lombard DB. Gray GS. Nadler LM, Sharpe AH: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993:262:907-909.
138. Freeman GJ, Gribben JG. Boussiotis VA. Ng JW, Restivo VA Jr. Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993:262:909-911.
139. Azuma M. ItoD. Yagita H. Okumura K, Phillips JH. Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
140. Guinan EC, Gribben JG. Boussiotis VA, Freeman GJ. Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994:84: 3261-3282.
141. Schwartz RH: Costimulation of T lymphocytes: The role of CD28. CTLA-4. and BB7/ BBI in IL-2 production and immunotherapy. Cell 1992;71:1065-1068.
142. Larsen CP. Ritchie SC. Pearson TC, Linsley PS, Lowry RP: Functional expression of the costimulatory molecule. B7/BB1. on murine dendritic cell populations. J Exp Med 1992; 176:1215-1220.
143. Razi-Wolf Z, Freeman GJ. Galvin F. Bena-cerraf B. Nadlcr L, Reiser H: Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sei USA 1992;89:4210-4214.
144. Linsley O. Ledbetter J: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11:191-212.
145. June CH. Bluestonc JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 1994:15:321-331.
146. Gross JA, Calla E, Allison JP: Identification and distribution of the costimulalorv receptor CD28 in the mouse. J Immunol 1992:149: 380-388.
147. Brunet JF, Denizot F, Luciani MF, Roux-Dosscto M, Suzan M. Mattei MG. Golstcin P: A new member of the immunoglobulin super-family - CTLA-4. Nature 1987:328:267-270.
148. Linsley PS, Greene JL, Tan P. Bradshaw J. Ledbetter JA. Anasetti C, Damle NK: Co-expression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176:1595-1604.
149. Lenshow DJ, Zeng Y. Thistlethwaite JR. Montag A. Brady W. Gibson MG. Linsley PS, Bluestonc JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4!g. Science 1992:257:789-792.
150. Turka LA. Linsley PS, Lin H. Brady W. Leiden JM. Wei RQ. Gibson ML, Zheng XG, Myrdal S, Gordon D, et a!.: T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sei USA 1993:178:1801-1806.
151. Lin H, Bolling SF. Linsley P. Wei RQ. Gordon D. Thompson CA. Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
152. Honda S, Campbell JJ. Andrew DP. Engelhardt B, Butcher BA, Wamock RA, Ye RD. Butcher EC: Ligand-induced adhesion to activated endothelium and to vascular cell adhesion molecule-1 in lymphocytes transfected with the N-formyl peptide receptor. J Immunol 1994;152:4026-4035.
153. Freedman AS, Munro JM, Rice GE. Bevilac-qua MP. Morimoto C. McIntyre BW, Rhyn-hart K. Pober JS, Nadlcr LM: Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990:249:1030-1033.
154. Rice GE. Munro JM. Corless C, Bevilacqua MP: Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991:138:385-393.
155. Damle NK. Klussman K, Leytze G. Myrdal S. Aruffo A. Ledbetter JA. Linsley PS: Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 induces functional expression of CTLA-4. a second receptor forB7. J Immunol 1994:152:2686-2697.
156. Blazar BR, Taylor PA, Linsley PS. Vallera DA: In vivo blockade of CD28/CTLA4: B7/ BBI interaction with CTLA4-Ig reduces lethal murine gralt-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825.
157. Blazar BR, Taylor PA. Gray GS, Vallera DA: The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inocula. Transplantation 1994:58:1422-1426.
158. Wallace PM, Johnson JS. MacMaster JF. Kennedy KA, Gladstone P. Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994;58:602-610.
159. Harring R. Pelletier J. Lubbc K, Takci F. Mcrluzzi VJ: Reduction in the severity of graft-versus-host disease and increased survival in allogenic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1 alpha and M ALA-2. Transplantation 1991:52:842-845.
160. Blazar BR. Taylor PA, Panoskaltsis-Mortari A, Gray GS. Vallera DA: Coblockade of the LFALICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995:85:2607- 2618.
161. Clark EA. Ledbetter JA: How B and T cells talk to each other. Nature 1994:367:425- 428.
162. Clark KK. Siadak AW. Stebbins MR, Wallace PW: Blockade of CD40-PG39 interaction with monoclonal antibody anti-GP39 reduces the lethality in murine acute graft-vs-host disease. Blood 1995;86(suppl l):576.
163. Blazar BR. Taylor PA, Panoskaltsis-Mortari A, Noëlle RJ. Vallera DA: The role of donor T cell CD40 ligand expression and T cell:B cell interactions in acute graft-versus-host disease. Blood 1995;86(suppl l):623.
164. Schlegel PG, Vaysburd M. Chen Y, Butcher E, Chao NJ: Inhibition ofT cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 1995:155: 3856-3865